US4709016A
(en)
|
1982-02-01 |
1987-11-24 |
Northeastern University |
Molecular analytical release tags and their use in chemical analysis
|
US5650270A
(en)
|
1982-02-01 |
1997-07-22 |
Northeastern University |
Molecular analytical release tags and their use in chemical analysis
|
US4650750A
(en)
|
1982-02-01 |
1987-03-17 |
Giese Roger W |
Method of chemical analysis employing molecular release tag compounds
|
US5516931A
(en)
|
1982-02-01 |
1996-05-14 |
Northeastern University |
Release tag compounds producing ketone signal groups
|
US5360811A
(en)
|
1990-03-13 |
1994-11-01 |
Hoechst-Roussel Pharmaceuticals Incorporated |
1-alkyl-, 1-alkenyl-, and 1-alkynylaryl-2-amino-1,3-propanediols and related compounds as anti-inflammatory agents
|
JP3545461B2
(ja)
|
1993-09-10 |
2004-07-21 |
エーザイ株式会社 |
二環式ヘテロ環含有スルホンアミド誘導体
|
US6281230B1
(en)
|
1996-07-24 |
2001-08-28 |
Celgene Corporation |
Isoindolines, method of use, and pharmaceutical compositions
|
US6306663B1
(en)
|
1999-02-12 |
2001-10-23 |
Proteinex, Inc. |
Controlling protein levels in eucaryotic organisms
|
DK1235830T3
(da)
|
1999-12-10 |
2004-03-29 |
Pfizer Prod Inc |
Pyrrolo[2,3-d]pyrimidin-forbindelser som proteinkinaseinhibitorer
|
DE10002509A1
(de)
|
2000-01-21 |
2001-07-26 |
Gruenenthal Gmbh |
Substituierte Glutarimide
|
WO2001064681A2
(en)
|
2000-02-28 |
2001-09-07 |
Sugen, Inc. |
3-(pyrolyllactone)-2-indolinone compounds as kinase inhibitors
|
PE20020354A1
(es)
|
2000-09-01 |
2002-06-12 |
Novartis Ag |
Compuestos de hidroxamato como inhibidores de histona-desacetilasa (hda)
|
US7208157B2
(en)
|
2000-09-08 |
2007-04-24 |
California Institute Of Technology |
Proteolysis targeting chimeric pharmaceutical
|
US7041298B2
(en)
|
2000-09-08 |
2006-05-09 |
California Institute Of Technology |
Proteolysis targeting chimeric pharmaceutical
|
WO2002078617A2
(en)
|
2001-03-28 |
2002-10-10 |
University Of South Florida |
Materials and methods for treatment of cancer and identification of anti-cancer compounds
|
EP1389617B1
(en)
|
2001-04-27 |
2007-01-03 |
Zenyaku Kogyo Kabushiki Kaisha |
Heterocyclic compound and antitumor agent containing the same as active ingredient
|
TWI329105B
(en)
|
2002-02-01 |
2010-08-21 |
Rigel Pharmaceuticals Inc |
2,4-pyrimidinediamine compounds and their uses
|
ES2319894T3
(es)
|
2002-08-14 |
2009-05-14 |
Silence Therapeutics Aktiengesellschaft |
Uso de la proteina quinasa-n-beta.
|
WO2004089925A1
(en)
|
2003-04-03 |
2004-10-21 |
Semafore Pharmaceuticals, Inc. |
Pi-3 kinase inhibitor prodrugs
|
NZ543897A
(en)
|
2003-05-30 |
2009-04-30 |
Gemin X Pharmaceuticals Canada |
Triheterocyclic compounds, compositions, and methods for treating cancer or viral diseases
|
CN100577680C
(zh)
|
2003-07-03 |
2010-01-06 |
宾夕法尼亚大学理事会 |
对Syk激酶表达的抑制
|
ES2385831T3
(es)
|
2003-12-11 |
2012-08-01 |
Board Of Regents, The University Of Texas System |
Compuestos para el tratamiento de enfermedades celulares proliferativas
|
JP4398263B2
(ja)
|
2004-01-13 |
2010-01-13 |
富士通株式会社 |
経路設計方法
|
US7436318B2
(en)
|
2004-04-19 |
2008-10-14 |
Atg Designworks, Llc |
Self contained device for displaying electronic information
|
DK1761540T3
(en)
|
2004-05-13 |
2016-11-21 |
Icos Corp |
Quinazolinones as inhibitors of human phosphatidylinositol 3-kinase DELTA
|
US20060005147A1
(en)
|
2004-06-30 |
2006-01-05 |
Hammack Jason L |
Methods and systems for controlling the display of maps aboard an aircraft
|
US20070010428A1
(en)
|
2004-09-03 |
2007-01-11 |
Mcmurray John S |
Inhibitors of signal transduction and activator of transcription 3
|
TWI380996B
(zh)
|
2004-09-17 |
2013-01-01 |
Hoffmann La Roche |
抗ox40l抗體
|
DE602006010979D1
(de)
|
2005-01-19 |
2010-01-21 |
Rigel Pharmaceuticals Inc |
Prodrugs aus 2,4-pyrimidindiamin-verbindungen und ihre verwendungen
|
AU2006216510A1
(en)
|
2005-02-25 |
2006-08-31 |
The Regent Of The University Of Michigan |
Small molecule inhibitors of STAT3 and the uses thereof
|
EP1866339B8
(en)
|
2005-03-25 |
2021-12-01 |
GITR, Inc. |
Gitr binding molecules and uses therefor
|
ES2493466T3
(es)
|
2005-05-12 |
2014-09-11 |
Abbvie Bahamas Ltd. |
Promotores de la apoptosis
|
GB0510390D0
(en)
|
2005-05-20 |
2005-06-29 |
Novartis Ag |
Organic compounds
|
CN105330741B
(zh)
|
2005-07-01 |
2023-01-31 |
E.R.施贵宝&圣斯有限责任公司 |
抗程序性死亡配体1(pd-l1)的人单克隆抗体
|
US7402325B2
(en)
|
2005-07-28 |
2008-07-22 |
Phoenix Biotechnology, Inc. |
Supercritical carbon dioxide extract of pharmacologically active components from Nerium oleander
|
US20080139456A1
(en)
|
2005-09-30 |
2008-06-12 |
Burke Terrence R |
Macrocyclic Sh2 Domain Binding Inhibitors
|
CA2623768C
(en)
|
2005-10-07 |
2016-04-12 |
Exelixis, Inc. |
N-(3-amino-quinoxalin-2-yl) -sulfonamide derivatives and their use as phosphatidylinositol 3-kinase inhibitors
|
CA2625219A1
(en)
|
2005-10-13 |
2007-04-19 |
Orchid Research Laboratories Limited |
Heterocyclic compounds as pstat3/il-6 inhibitors
|
DK1951684T3
(en)
|
2005-11-01 |
2016-10-24 |
Targegen Inc |
BIARYLMETAPYRIMIDIN kinase inhibitors
|
MY162590A
(en)
|
2005-12-13 |
2017-06-30 |
Incyte Holdings Corp |
Heteroaryl substituted pyrrolo[2,3-b] pyridines and pyrrolo[2,3-b] pyrimidines as janus kinase inhibitors
|
PL1966130T3
(pl)
|
2005-12-23 |
2014-05-30 |
Zealand Pharma As |
Zmodyfikowane związki mimetyczne lizyny
|
JO2660B1
(en)
|
2006-01-20 |
2012-06-17 |
نوفارتيس ايه جي |
Pi-3 inhibitors and methods of use
|
AR060631A1
(es)
|
2006-04-26 |
2008-07-02 |
Piramed Ltd |
Derivados de pirimidina y su uso como inhibidores de fosfatidilnositol 3-quinasa (pi3k)
|
WO2007136858A2
(en)
|
2006-05-19 |
2007-11-29 |
H. Lee Moffitt Cancer Center & Research Institute |
Small molecule inhibitors of stat3 with anti-tumor activity
|
EP2081435B1
(en)
|
2006-09-22 |
2016-05-04 |
Pharmacyclics LLC |
Inhibitors of bruton's tyrosine kinase
|
UA95978C2
(ru)
|
2006-10-02 |
2011-09-26 |
Оцука Фармас'Ютікел Ко., Лтд. |
Ингибитор активации stat3/5
|
WO2008067270A1
(en)
|
2006-11-27 |
2008-06-05 |
Government Of The United States Of America, Represented By The Secretary, Department Of Health And Human Services |
Macrocyclic grb2 sh2 domain-binding inhibitors
|
BRPI0808888B8
(pt)
|
2007-03-12 |
2021-05-25 |
Cytopia Res Pty Ltd |
composto de fenil amino pirimidina para uso no tratamento de uma doença associada à quinase, processo para a preparação do composto, composição farmacêutica, e, implante
|
WO2008118802A1
(en)
|
2007-03-23 |
2008-10-02 |
Regents Of The University Of Minnesota |
Therapeutic compounds
|
EP1987839A1
(en)
|
2007-04-30 |
2008-11-05 |
I.N.S.E.R.M. Institut National de la Sante et de la Recherche Medicale |
Cytotoxic anti-LAG-3 monoclonal antibody and its use in the treatment or prevention of organ transplant rejection and autoimmune disease
|
PE20090717A1
(es)
|
2007-05-18 |
2009-07-18 |
Smithkline Beecham Corp |
Derivados de quinolina como inhibidores de la pi3 quinasa
|
WO2008156644A2
(en)
|
2007-06-14 |
2008-12-24 |
Frank David A |
Stat modulators
|
ES2591281T3
(es)
|
2007-07-12 |
2016-11-25 |
Gitr, Inc. |
Terapias de combinación que emplean moléculas de enlazamiento a GITR
|
WO2009032338A1
(en)
|
2007-09-09 |
2009-03-12 |
University Of Florida Research Foundation |
Apratoxin therapeutic agents: mechanism and methods of treatment
|
EP2044949A1
(en)
|
2007-10-05 |
2009-04-08 |
Immutep |
Use of recombinant lag-3 or the derivatives thereof for eliciting monocyte immune response
|
WO2009073620A2
(en)
|
2007-11-30 |
2009-06-11 |
Newlink Genetics |
Ido inhibitors
|
FR2927330B1
(fr)
|
2008-02-07 |
2010-02-19 |
Sanofi Aventis |
Derives de 5,6-bisaryl-2-pyridine-carboxamide, leur preparation et leur application en therapeutique comme antagonistes des recepteurs a l'urotensine ii
|
SI2288610T1
(sl)
|
2008-03-11 |
2016-11-30 |
Incyte Holdings Corporation |
Derivati azetidina in ciklobutana kot inhibitorji jak
|
CA2722159C
(en)
|
2008-04-24 |
2016-04-05 |
Newlink Genetics Corporation |
Substituted phenylimidazole compounds and their use as ido inhibitors
|
US8338439B2
(en)
|
2008-06-27 |
2012-12-25 |
Celgene Avilomics Research, Inc. |
2,4-disubstituted pyrimidines useful as kinase inhibitors
|
AU2009268841B2
(en)
|
2008-07-08 |
2014-02-06 |
Board Of Regents, The University Of Texas System |
Novel inhibitors of proliferation and activation of signal transducer and activator of transcription (STATS)
|
AR072999A1
(es)
|
2008-08-11 |
2010-10-06 |
Medarex Inc |
Anticuerpos humanos que se unen al gen 3 de activacion linfocitaria (lag-3) y los usos de estos
|
WO2010077589A2
(en)
|
2008-12-08 |
2010-07-08 |
The Regents Of The University Of Michigan Office Of Technology Transfer |
Stat3 inhibitors and therapeutic methods using the same
|
SI2376535T1
(sl)
|
2008-12-09 |
2017-07-31 |
F. Hoffmann-La Roche Ag |
Protitelesa anti-pd-l1 in njihova uporaba za izboljšanje funkcije celic t
|
US8921037B2
(en)
|
2008-12-16 |
2014-12-30 |
Bo Han |
PF4-depleted platelet rich plasma preparations and methods for hard and soft tissue repair
|
WO2010118309A2
(en)
|
2009-04-10 |
2010-10-14 |
Board Of Regents, The University Of Texas System |
Inhibitors of stat3 and uses thereof
|
CA2758916A1
(en)
|
2009-04-15 |
2010-10-21 |
Pui-Kai Li |
Curcumin analogs as dual jak2/stat3 inhibitors and methods of making and using the same
|
LT3023438T
(lt)
|
2009-09-03 |
2020-05-11 |
Merck Sharp & Dohme Corp. |
Anti-gitr antikūnai
|
US8722720B2
(en)
|
2009-10-28 |
2014-05-13 |
Newlink Genetics Corporation |
Imidazole derivatives as IDO inhibitors
|
CA2781706A1
(en)
|
2009-11-24 |
2011-06-03 |
The Ohio State University |
Transcription factor inhibitors and related compositions, formulations and methods
|
ES2722300T3
(es)
|
2009-12-10 |
2019-08-09 |
Hoffmann La Roche |
Anticuerpos que se unen preferentemente al dominio extracelular 4 de CSF1R y su uso
|
US8445517B2
(en)
|
2009-12-11 |
2013-05-21 |
Dana-Farber Cancer Institute |
Stat modulators
|
EA022458B1
(ru)
|
2009-12-28 |
2016-01-29 |
Дженерал Инкорпорейтед Ассошиэйшн Фарма Вэлли Проджект Саппортинг Организейшн |
1,3,4-оксадиазол-2-карбоксамидное соединение
|
ME03447B
(me)
|
2010-03-04 |
2020-01-20 |
Macrogenics Inc |
Anтitela reakтivna sa b7-нз, njihovi imunološki akтivni fragmenтi i upotreba
|
CA2789076C
(en)
|
2010-03-05 |
2017-11-21 |
F. Hoffmann-La Roche Ag |
Antibodies against human colony stimulating factor-1 receptor and uses thereof
|
BR112012022046A2
(pt)
|
2010-03-05 |
2017-02-14 |
F Hoffamann-La Roche Ag |
''anticorpo,composição farmacêutica,ácido nucleico ,vetores de expressão,célula hospedeira e método para a produção de um anticorpo recombinante''.
|
US8206715B2
(en)
|
2010-05-04 |
2012-06-26 |
Five Prime Therapeutics, Inc. |
Antibodies that bind colony stimulating factor 1 receptor (CSF1R)
|
EP2585464A2
(en)
|
2010-06-22 |
2013-05-01 |
University Of Central Florida Research Foundation, Inc. |
Substituted 2-(9h-purin-9-yl) acetic acid analogues as inhibitors of stat3
|
WO2012003281A2
(en)
|
2010-06-30 |
2012-01-05 |
Brandeis University |
Small-molecule-targeted protein degradation
|
JP2013537535A
(ja)
|
2010-08-02 |
2013-10-03 |
ユニバーシティ オブ セントラル フロリダ リサーチ ファウンデーション,インコーポレイテッド |
Statタンパク質の阻害剤としての、置換2−ヒドロキシ−4−(2−(フェニルスルホンアミド)アセトアミド)安息香酸類似体
|
KR101527300B1
(ko)
|
2010-09-09 |
2015-06-09 |
화이자 인코포레이티드 |
4-1bb 결합 분자
|
US9500653B2
(en)
|
2010-12-07 |
2016-11-22 |
Yale University |
Small-molecule hydrophobic tagging of fusion proteins and induced degradation of same
|
KR102062407B1
(ko)
|
2010-12-09 |
2020-01-03 |
더 트러스티스 오브 더 유니버시티 오브 펜실바니아 |
암을 치료하기 위한 키메릭 항원 수용체 변형 t 세포의 용도
|
WO2012078982A2
(en)
|
2010-12-09 |
2012-06-14 |
The Ohio State University |
Xzh-5 inhibits constitutive and interleukin-6-induced stat3 phosphorylation in human hepatocellular carcinoma cells
|
WO2012097351A1
(en)
|
2011-01-14 |
2012-07-19 |
The Ohio State University Research Foundation |
Materials and methods to inhibit multiple myeloma cancer cells
|
WO2012142615A2
(en)
|
2011-04-14 |
2012-10-18 |
Board Of Regents, The University Of Texas System |
Auranofin and auranofin analogs useful to treat proliferative disease and disorders
|
NO2694640T3
(es)
|
2011-04-15 |
2018-03-17 |
|
|
LT2699264T
(lt)
|
2011-04-20 |
2018-07-10 |
Medimmune, Llc |
Antikūnai ir kitos molekulės, kurios jungiasi prie b7-h1 ir pd-1
|
KR101981873B1
(ko)
|
2011-11-28 |
2019-05-23 |
메르크 파텐트 게엠베하 |
항-pd-l1 항체 및 그의 용도
|
CN104159921B
(zh)
|
2011-12-15 |
2018-05-04 |
霍夫曼-拉罗奇有限公司 |
针对人csf-1r的抗体及其用途
|
CN117736134A
(zh)
|
2012-01-12 |
2024-03-22 |
耶鲁大学 |
通过e3泛素连接酶增强靶蛋白质及其他多肽降解的化合物和方法
|
WO2013106646A2
(en)
|
2012-01-12 |
2013-07-18 |
Yale University |
Compounds and methods for the inhibition of vcb e3 ubiquitin ligase
|
KR20140127855A
(ko)
|
2012-02-06 |
2014-11-04 |
제넨테크, 인크. |
Csf1r 억제제를 사용하는 조성물 및 방법
|
AR090263A1
(es)
|
2012-03-08 |
2014-10-29 |
Hoffmann La Roche |
Terapia combinada de anticuerpos contra el csf-1r humano y las utilizaciones de la misma
|
EP2847220A1
(en)
|
2012-05-11 |
2015-03-18 |
Five Prime Therapeutics, Inc. |
Methods of treating conditions with antibodies that bind colony stimulating factor 1 receptor (csf1r)
|
JP6290871B2
(ja)
|
2012-05-25 |
2018-03-07 |
ザ ガヴァーニング カウンシル オブ ザ ユニヴァーシティ オブ トロント |
新しいサリチル酸誘導体、薬学上許容可能なその塩、その組成物及びその使用方法
|
EP2861562B1
(en)
|
2012-06-14 |
2018-05-09 |
Mayo Foundation For Medical Education And Research |
Pyrazole derivatives as inhibitors of stat3
|
AR091649A1
(es)
|
2012-07-02 |
2015-02-18 |
Bristol Myers Squibb Co |
Optimizacion de anticuerpos que se fijan al gen de activacion de linfocitos 3 (lag-3) y sus usos
|
EP2884971A4
(en)
|
2012-08-16 |
2016-01-06 |
Ohio State Innovation Foundation |
STAT3 INHIBITORS AND THEIR ANTICANCER USE
|
AU2013308635A1
(en)
|
2012-08-31 |
2015-03-12 |
Five Prime Therapeutics, Inc. |
Methods of treating conditions with antibodies that bind colony stimulating factor 1 receptor (CSF1R)
|
MX2015003188A
(es)
|
2012-09-19 |
2015-07-17 |
Hoffmann La Roche |
2-oxo-2,3,4,5-tetrahidro-1 h-benzo[b]diazepinas y su uso en el tratamiento de cancer.
|
WO2014063061A1
(en)
|
2012-10-19 |
2014-04-24 |
Dana-Farber Cancer Institute, Inc. |
Hydrophobically tagged small molecules as inducers of protein degradation
|
WO2014070859A1
(en)
|
2012-10-30 |
2014-05-08 |
H. Lee Moffitt Cancer Center And Research Institute, Inc. |
Stat3 dimerization inhibitors
|
GB201311910D0
(en)
|
2013-07-03 |
2013-08-14 |
Glaxosmithkline Ip Dev Ltd |
Novel Compounds
|
US9802888B2
(en)
|
2013-03-22 |
2017-10-31 |
University Of Hawaii |
STAT3 inhibitors
|
WO2014205416A1
(en)
|
2013-06-20 |
2014-12-24 |
University Of Hawaii |
Novel sesquiterpenoid stat3 inhibitors
|
CA2925084A1
(en)
|
2013-11-18 |
2015-05-21 |
F. Hoffmann-La Roche Ag |
Tetrahydro-benzodiazepinones
|
KR20210132233A
(ko)
|
2014-04-14 |
2021-11-03 |
아비나스 오퍼레이션스, 인코포레이티드 |
단백질분해의 이미드-기초된 조절인자 및 연관된 이용 방법
|
US20180228907A1
(en)
|
2014-04-14 |
2018-08-16 |
Arvinas, Inc. |
Cereblon ligands and bifunctional compounds comprising the same
|
US20160058872A1
(en)
|
2014-04-14 |
2016-03-03 |
Arvinas, Inc. |
Imide-based modulators of proteolysis and associated methods of use
|
ES2843973T3
(es)
|
2014-06-27 |
2021-07-21 |
Celgene Corp |
Composiciones y métodos para inducir cambios conformacionales en cereblon y otras ubiquitina ligasas E3
|
US20160022642A1
(en)
|
2014-07-25 |
2016-01-28 |
Yale University |
Compounds Useful for Promoting Protein Degradation and Methods Using Same
|
US10071164B2
(en)
|
2014-08-11 |
2018-09-11 |
Yale University |
Estrogen-related receptor alpha based protac compounds and associated methods of use
|
KR101697062B1
(ko)
|
2014-08-26 |
2017-01-18 |
한국생명공학연구원 |
물에 대한 용해도가 개선된 신규 제라닐 프라보노이드 유도체, 이의 제조 방법 및 이를 유효성분으로 포함하는 암 예방 및 치료용 약학적 조성물
|
KR20160066490A
(ko)
|
2014-12-02 |
2016-06-10 |
주식회사 씨앤드씨신약연구소 |
헤테로사이클 유도체 및 그의 용도
|
WO2016105518A1
(en)
|
2014-12-23 |
2016-06-30 |
Dana-Farber Cancer Institute, Inc. |
Methods to induce targeted protein degradation through bifunctional molecules
|
US9694084B2
(en)
|
2014-12-23 |
2017-07-04 |
Dana-Farber Cancer Institute, Inc. |
Methods to induce targeted protein degradation through bifunctional molecules
|
WO2016115455A2
(en)
|
2015-01-15 |
2016-07-21 |
University Of Pittsburgh - Of The Commonwealth System Of Higher Education |
6-aryl-7-substituted-3-(1h-pyrazol-5-yl)-7h-[1,2,4]triazolo[3,4-b][1,3,4]thiadiazines as inhibitors of the stat3 pathway with anti-proliferative activity
|
WO2016118666A1
(en)
|
2015-01-20 |
2016-07-28 |
Arvinas, Inc. |
Compounds and methods for the targeted degradation of the androgen receptor
|
US20170327469A1
(en)
|
2015-01-20 |
2017-11-16 |
Arvinas, Inc. |
Compounds and methods for the targeted degradation of androgen receptor
|
CN112494653A
(zh)
|
2015-02-05 |
2021-03-16 |
特尔诺沃有限公司 |
用于治疗癌症的irs/stat3双重调节剂与抗癌剂的组合
|
BR112017019751A2
(pt)
|
2015-03-18 |
2018-05-29 |
Arvinas Inc |
composto bifuncional, composição farmacêutica, e, métodos para tratar ou prevenir uma doença ou um distúrbio, e para degradar uma proteína alvo em uma célula
|
GB201506871D0
(en)
|
2015-04-22 |
2015-06-03 |
Glaxosmithkline Ip Dev Ltd |
Novel compounds
|
WO2016197032A1
(en)
|
2015-06-04 |
2016-12-08 |
Arvinas, Inc. |
Imide-based modulators of proteolysis and associated methods of use
|
US20180147202A1
(en)
|
2015-06-05 |
2018-05-31 |
Arvinas, Inc. |
TANK-BINDING KINASE-1 PROTACs AND ASSOCIATED METHODS OF USE
|
SE539204C2
(en)
|
2015-06-05 |
2017-05-09 |
Glactone Pharma Dev Ab |
Ether analogues of galiellalactone
|
CN105085620B
(zh)
|
2015-06-25 |
2018-05-08 |
中山大学附属第一医院 |
一种靶向泛素化降解Smad3的化合物
|
WO2017007612A1
(en)
|
2015-07-07 |
2017-01-12 |
Dana-Farber Cancer Institute, Inc. |
Methods to induce targeted protein degradation through bifunctional molecules
|
CA2988430A1
(en)
|
2015-07-10 |
2017-01-19 |
Arvinas, Inc. |
Mdm2-based modulators of proteolysis and associated methods of use
|
WO2017011590A1
(en)
|
2015-07-13 |
2017-01-19 |
Arvinas, Inc. |
Alanine-based modulators of proteolysis and associated methods of use
|
US10772962B2
(en)
|
2015-08-19 |
2020-09-15 |
Arvinas Operations, Inc. |
Compounds and methods for the targeted degradation of bromodomain-containing proteins
|
KR102650026B1
(ko)
|
2015-09-18 |
2024-03-22 |
메르크 파텐트 게엠베하 |
Irak 억제제로서의 헤테로아릴 화합물 및 이의 용도
|
WO2017079267A1
(en)
|
2015-11-02 |
2017-05-11 |
Yale University |
Proteolysis targeting chimera compounds and methods of preparing and using same
|
WO2017117473A1
(en)
|
2015-12-30 |
2017-07-06 |
Dana-Farber Cancer Institute, Inc. |
Bifunctional molescules for her3 degradation and methods of use
|
US20190016703A1
(en)
|
2015-12-30 |
2019-01-17 |
Dana-Farber Cancer Institute, Inc. |
Bifunctional compounds for her3 degradation and methods of use
|
AU2017232906B2
(en)
|
2016-03-16 |
2022-03-31 |
H. Lee Moffitt Cancer Center & Research Institute, Inc. |
Small molecules against cereblon to enhance effector T cell function
|
US20170281784A1
(en)
|
2016-04-05 |
2017-10-05 |
Arvinas, Inc. |
Protein-protein interaction inducing technology
|
US10759808B2
(en)
|
2016-04-06 |
2020-09-01 |
The Regents Of The University Of Michigan |
Monofunctional intermediates for ligand-dependent target protein degradation
|
RU2743432C2
(ru)
|
2016-04-06 |
2021-02-18 |
Дзе Риджентс Оф Дзе Юниверсити Оф Мичиган |
Деструкторы белка mdm2
|
WO2017197055A1
(en)
|
2016-05-10 |
2017-11-16 |
C4 Therapeutics, Inc. |
Heterocyclic degronimers for target protein degradation
|
WO2017197046A1
(en)
|
2016-05-10 |
2017-11-16 |
C4 Therapeutics, Inc. |
C3-carbon linked glutarimide degronimers for target protein degradation
|
WO2017197051A1
(en)
|
2016-05-10 |
2017-11-16 |
C4 Therapeutics, Inc. |
Amine-linked c3-glutarimide degronimers for target protein degradation
|
WO2017197056A1
(en)
|
2016-05-10 |
2017-11-16 |
C4 Therapeutics, Inc. |
Bromodomain targeting degronimers for target protein degradation
|
CN109562113A
(zh)
|
2016-05-10 |
2019-04-02 |
C4医药公司 |
用于靶蛋白降解的螺环降解决定子体
|
WO2017201069A1
(en)
|
2016-05-18 |
2017-11-23 |
Biotheryx, Inc. |
Oxoindoline derivatives as protein function modulators
|
WO2017201449A1
(en)
|
2016-05-20 |
2017-11-23 |
Genentech, Inc. |
Protac antibody conjugates and methods of use
|
GB201610147D0
(en)
|
2016-06-10 |
2016-07-27 |
Glaxosmithkline Ip Dev Ltd |
Novel compounds
|
EP3544970B1
(en)
|
2016-11-22 |
2021-11-17 |
Dana-Farber Cancer Institute, Inc. |
Inhibitors of interleukin-1 receptor-associated kinases and uses thereof
|
SE540295C2
(en)
|
2016-12-05 |
2018-05-29 |
Glactone Pharma Dev Ab |
Sulfonamide analogues of galiellalactone
|
EP3570836A4
(en)
|
2017-01-23 |
2020-08-19 |
The University of Hawaii |
2-ARYLSULFONAMIDO-N-ARYLACETAMIDE DERIVATIZED STAT3 INHIBITORS
|
AU2018215212B2
(en)
|
2017-01-31 |
2022-06-02 |
Arvinas Operations, Inc. |
Cereblon ligands and bifunctional compounds comprising the same
|
WO2018237026A1
(en)
|
2017-06-20 |
2018-12-27 |
C4 Therapeutics, Inc. |
N / O-LINKED DEGRONS AND DEGRONIMERS FOR DEGRADATION OF PROTEINS
|
EP3679026A1
(en)
|
2017-09-04 |
2020-07-15 |
C4 Therapeutics, Inc. |
Glutarimide
|
IL307995A
(en)
|
2017-09-22 |
2023-12-01 |
Kymera Therapeutics Inc |
Protein compounds and their uses
|
US11358948B2
(en)
|
2017-09-22 |
2022-06-14 |
Kymera Therapeutics, Inc. |
CRBN ligands and uses thereof
|
WO2019084030A1
(en)
|
2017-10-24 |
2019-05-02 |
Genentech, Inc. |
(4-HYDROXYPYRROLIDIN-2-YL) -HYDROXAMATE COMPOUNDS AND METHODS OF USE
|
EP3700901A1
(en)
|
2017-10-24 |
2020-09-02 |
Genentech, Inc. |
(4-hydroxypyrrolidin-2-yl)-heterocyclic compounds and methods of use thereof
|
WO2019099868A2
(en)
|
2017-11-16 |
2019-05-23 |
C4 Therapeutics, Inc. |
Degraders and degrons for targeted protein degradation
|
WO2019099926A1
(en)
|
2017-11-17 |
2019-05-23 |
Arvinas, Inc. |
Compounds and methods for the targeted degradation of interleukin-1 receptor-associated kinase 4 polypeptides
|
MX2020006812A
(es)
|
2017-12-26 |
2020-11-06 |
Kymera Therapeutics Inc |
Degradadores de cinasas asociadas al receptor de interleucina-1 (irak) y usos de los mismos.
|
US11512080B2
(en)
|
2018-01-12 |
2022-11-29 |
Kymera Therapeutics, Inc. |
CRBN ligands and uses thereof
|
EP3737666A4
(en)
|
2018-01-12 |
2022-01-05 |
Kymera Therapeutics, Inc. |
PROTEIN DEGRADANTS AND USES THEREOF
|
CN112020358A
(zh)
|
2018-02-23 |
2020-12-01 |
达纳-法伯癌症研究所有限公司 |
诱导蛋白质选择性降解的小分子及其用途
|
EP3578561A1
(en)
|
2018-06-04 |
2019-12-11 |
F. Hoffmann-La Roche AG |
Spiro compounds
|
WO2020010177A1
(en)
|
2018-07-06 |
2020-01-09 |
Kymera Therapeutics, Inc. |
Tricyclic crbn ligands and uses thereof
|
WO2020010210A1
(en)
|
2018-07-06 |
2020-01-09 |
Kymera Therapeutics, Inc. |
Mertk degraders and uses thereof
|
WO2020010227A1
(en)
|
2018-07-06 |
2020-01-09 |
Kymera Therapeutics, Inc. |
Protein degraders and uses thereof
|
US11352350B2
(en)
|
2018-11-30 |
2022-06-07 |
Kymera Therapeutics, Inc. |
IRAK degraders and uses thereof
|
EP3947403A1
(en)
*
|
2019-03-29 |
2022-02-09 |
The Regents Of The University Of Michigan |
Stat3 protein degraders
|
KR20220006139A
(ko)
|
2019-04-05 |
2022-01-14 |
카이메라 쎄라퓨틱스 인코포레이티드 |
Stat 분해제 및 이의 용도
|
KR20220032063A
(ko)
|
2019-06-28 |
2022-03-15 |
카이메라 쎄라퓨틱스 인코포레이티드 |
Irak 분해제 및 이의 용도
|
US20230089916A1
(en)
|
2019-06-28 |
2023-03-23 |
Kymera Therapeutics, Inc. |
Irak degraders and uses thereof
|
WO2021011631A1
(en)
|
2019-07-15 |
2021-01-21 |
Kymera Therapeutics, Inc. |
Fused-glutarimide crbn ligands and uses thereof
|
US20230093080A1
(en)
|
2019-07-15 |
2023-03-23 |
Kymera Therapeutics, Inc. |
Protein degraders and uses thereof
|
WO2021011871A1
(en)
|
2019-07-17 |
2021-01-21 |
Kymera Therapeutics, Inc. |
Mertk degraders and uses thereof
|
US20230132715A1
(en)
|
2019-07-17 |
2023-05-04 |
Kymera Therapeutics, Inc. |
Irak degraders and uses thereof
|
EP4072591A1
(en)
|
2019-12-10 |
2022-10-19 |
Kymera Therapeutics, Inc. |
Irak degraders and uses thereof
|
US11591332B2
(en)
|
2019-12-17 |
2023-02-28 |
Kymera Therapeutics, Inc. |
IRAK degraders and uses thereof
|
US20230219945A1
(en)
|
2019-12-17 |
2023-07-13 |
Kymera Therapeutics, Inc. |
Irak degraders and uses thereof
|
IL293917A
(en)
|
2019-12-17 |
2022-08-01 |
Kymera Therapeutics Inc |
Iraq joints and their uses
|
WO2021158634A1
(en)
|
2020-02-03 |
2021-08-12 |
Kymera Therapeutics, Inc. |
Irak degraders and uses thereof
|